Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.

After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.

From innovation to legislation, the US audiology market is being shaped by cutting-edge technology from device makers and legislation from the Biden administration to get more hearing aids to those that need them.

French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.